scholarly journals Effectiveness of pneumococcal conjugate vaccination against invasive pneumococcal disease among children with and those without HIV infection: a systematic review and meta-analysis

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Hossein Molavi Vardanjani ◽  
Hodjat Borna ◽  
Ali Ahmadi
Keyword(s):  
Systematic Review ◽  
Hiv Infection ◽  
Invasive Pneumococcal Disease ◽  
Pneumococcal Disease ◽  
Meta Analysis ◽  
Conjugate Vaccination

scholarly journals Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis

2017 ◽  
Vol 5 (1) ◽  
pp. e51-e59 ◽  
Author(s):  
Tinevimbo Shiri ◽  
Samik Datta ◽  
Jason Madan ◽  
Alexander Tsertsvadze ◽  
Pamela Royle ◽  
...  
Keyword(s):  
Systematic Review ◽  
Invasive Pneumococcal Disease ◽  
Indirect Effects ◽  
Pneumococcal Disease ◽  
Meta Analysis ◽  
Conjugate Vaccination

scholarly journals Effectiveness of Pneumococcal Conjugate Vaccination against Invasive Pneumococcal Disease among children with and those without HIV infection: A Systematic Review and Meta-Analysis

2019 ◽  
Author(s):  
Hossein Molavi Vardanjani ◽  
Hodjat Borna ◽  
Ali Ahmadi
Keyword(s):  
Systematic Review ◽  
Invasive Pneumococcal Disease ◽  
Pneumococcal Disease ◽  
Meta Analysis ◽  
Vaccination Strategy ◽  
Cochrane Library ◽  
Older Children ◽  
Vaccine Serotypes ◽  
The Cochrane Library ◽  
Conjugate Vaccination

Abstract Background: HIV-infected children are at a higher risk of Invasive Pneumococcal Disease (IPD) and its mortality, even in the era of antiretroviral therapy. Therefore, an effective vaccination strategy would be beneficial. To investigate the effectiveness of Pneumococcal Conjugate Vaccination (PCV) against IPD among HIV-Infected and HIV-Uninfected Children through a systematic review and meta-analysis. Methods: Observational studies and randomized trials on 7 years old or older children were searched in the Cochrane Library, Web of Science core collection, Embase, Medline/PubMed, and Google Scholar. Critical appraisal was done using the Cochrane risk of bias tool and the Newcastle-Ottawa quality assessment form. Effectiveness and efficacy of at least one dose of PCV was investigated among children with and without HIV considering subgroups of pneumococcal serotypes. We meta-analyzed the effect sizes using random-effects modeling. Results: Efficacy of PCV was estimated as 45.0% (31.2, 56.1) and 52.6% (25.7, 69.8) among HIV-infected and HIV-uninfected children, respectively. Effectiveness of PCV among HIV-infected children as -6.2% (-67.6, 32.7) was significantly lower than HIV-uninfected children 65.1% (47.3, 76.9). Effectiveness of PCV among HIV-infected children for IPDs caused by vaccine serotypes was estimated as 7.7(-66.7, 48.9), and for IPDs caused by non-vaccine serotypes was estimated as -402.8(-1856, -29.2). Conclusion: Unlike the evidence on the efficacy of PCV against IPD among both of HIV-infected and HIV-uninfected children, its effectiveness against IPD among HIV-infected children is much less limited. Review Registration The study protocol was registered at PROSPERO (registration ID: CRD42018108187).

scholarly journals 21. Systematic Review and Meta-Analysis of Pneumococcal Vaccine Effectiveness against Invasive Pneumococcal Disease among Adults

2021 ◽  
Vol 8 (Supplement_1) ◽  
pp. S134-S135
Author(s):  
Jennifer Loo Farrar ◽  
Miwako Kobayashi ◽  
Lana Childs ◽  
Tamara Pilishvili
Keyword(s):  
Systematic Review ◽  
Invasive Pneumococcal Disease ◽  
Pneumococcal Vaccine ◽  
Observational Studies ◽  
Pneumococcal Disease ◽  
English Literature ◽  
Meta Analysis ◽  
Vaccine Effectiveness ◽  
Vaccine Type ◽  
Effectiveness Studies

Abstract Background Two new pneumococcal conjugate vaccines (PCVs), PCV15 and PCV20, are anticipated to be licensed for use in U.S. adults in 2021. To help inform the U.S. Advisory Committee on Immunization Practices’ discussions on pneumococcal vaccine use among adults, we conducted a systematic review and meta-analysis. We specifically looked at efficacy or effectiveness of PCV13 and pneumococcal polysaccharide vaccine (PPSV23) against invasive pneumococcal disease (IPD) in adults. Methods We conducted a search of English literature published from 1998 – February 2021 on PCV13 and PPSV23 efficacy or effectiveness studies using eight major databases. Studies targeting adults with immunocompromising conditions were excluded. Title and abstract screening of identified studies and data abstraction were performed by two reviewers. Results were stratified by vaccine product, outcome evaluated (vaccine type (VT) or all IPD), study design, and effect measure. Random effects models were used to pool estimates by stratum. Results Of 3,422 citations reviewed, we identified 26 IPD studies; 4 on PCV13, 22 on PPSV23, 18 with all IPD, and 17 with VT-IPD (Table) as an outcome. Only one randomized-controlled trial (RCT) was identified for PCV13 with an efficacy of 52% (95% CI: 22%, 77%) against all IPD and 75% (95% CI: 41%, 91%) against VT-IPD. A pooled vaccine effectiveness (VE) estimate from three observational studies evaluating PCV13 was 56% (95% CI: 32%, 71%; I2 =12.8) against VT-IPD. Two RCTs evaluating PPSV23 reported efficacies against all IPD ranging between 79-86%; an additional RCT reported no IPD cases during RCT. Vaccine effectiveness estimates from 14 observational studies evaluating PPSV23 ranged between 29-76% against all IPD. Pooled VE estimates from 12 observational studies showed PPSV23 effectiveness against VT-IPD was 38% (95% CI: 28% to 46%; I2 =40.8). Table. Efficacy and effectiveness studies against vaccine-type invasive pneumococcal disease Conclusion Evidence suggests both pneumococcal vaccines are effective against VT-IPD in adults. Given that PCV15 and PCV20 are expected to be licensed based on immunogenicity data and no clinical efficacy data are available for these new vaccines, the findings from this review will help inform policy discussions on use of the new PCVs among adults. Disclosures All Authors: No reported disclosures

scholarly journals Incidence of invasive pneumococcal disease in immunocompromised patients: A systematic review and meta-analysis

2018 ◽  
Vol 24 ◽  
pp. 89-100 ◽  
Author(s):  
Mariëlle van Aalst ◽  
Felix Lötsch ◽  
René Spijker ◽  
Jan T.M. van der Meer ◽  
Miranda W. Langendam ◽  
...  
Keyword(s):  
Systematic Review ◽  
Invasive Pneumococcal Disease ◽  
Pneumococcal Disease ◽  
Meta Analysis ◽  
Immunocompromised Patients

scholarly journals Correction to: HIV infection and multidrug resistant tuberculosis: a systematic review and meta-analysis

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Zeeba Zahra Sultana ◽  
Farhana Ul Hoque ◽  
Joseph Beyene ◽  
Md. Akhlak-Ul-Islam ◽  
Md Hasinur Rahman Khan ◽  
...  
Keyword(s):  
Systematic Review ◽  
Hiv Infection ◽  
Meta Analysis ◽  
Multidrug Resistant ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis

An amendment to this paper has been published and can be accessed via the original article.

scholarly journals Prognostic factors for mortality in invasive pneumococcal disease in adult: a system review and meta-analysis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Hao Chen ◽  
Hiromi Matsumoto ◽  
Nobuyuki Horita ◽  
Yu Hara ◽  
Nobuaki Kobayashi ◽  
...  
Keyword(s):  
Invasive Pneumococcal Disease ◽  
Odds Ratio ◽  
Pneumococcal Disease ◽  
Web Of Science ◽  
Meta Analysis ◽  
Mortality Rates ◽  
Solid Organ ◽  
Factors Associated ◽  
System Review ◽  
Overall Mortality

AbstractRisk factors associated with mortality in invasive pneumococcal disease remain unclear. The present work is a meta-analysis of studies that enrolled only patients with invasive pneumococcal disease and reported on mortality. Potentially eligible reports were identified from PubMed, CHAHL, and Web of Science, comprising 26 reports in total. Overall mortality for invasive pneumococcal disease was reported as 20.8% (95% confidence interval (CI) 17.5–24%). Factors associated with mortality were age (odds ratio (OR) 3.04, 95% CI 2.5–3.68), nursing home (OR 1.62, 95% CI 1.13–2.32), nosocomial infection (OR 2.10, 95% CI 1.52–2.89), septic shock (OR 13.35, 95% CI 4.54–39.31), underlying chronic diseases (OR 2.34, 95% CI 1.78–3.09), solid organ tumor (OR 5.34, 95% CI 2.07–13.74), immunosuppressed status (OR 1.67, 95% CI 1.31–2.14), and alcohol abuse (OR 3.14, 95% CI 2.13–4.64). Mortality rates with invasive pneumococcal disease remained high, and these findings may help clinicians provide appropriate initial treatment for this disease.

Sign in / Sign up

Export Citation Format

Share Document